RG6356 (RO7434656)
Acute Myeloid Leukemia
Key Facts
About Chugai Pharmaceutical
Chugai Pharmaceutical's mission is to create innovative, best-in-class therapeutics that contribute to human health worldwide, with a strategic focus on oncology and niche specialty areas. Its defining achievement is the construction of a highly successful, decades-long strategic alliance with Roche, which provides a unique two-way pipeline flow, global scale, and financial stability. The company's strategy centers on maintaining a powerful independent R&D engine to generate proprietary assets while simultaneously co-developing and commercializing Roche's global portfolio in its key markets. This model has established Chugai as Japan's premier biopharmaceutical innovator and a vital node in Roche's global network.
View full company profileTherapeutic Areas
Other Acute Myeloid Leukemia Drugs
| Drug | Company | Phase |
|---|---|---|
| AFM28 | Affimed | Phase 1/2 |
| AML (N-Act) AI | Biostate AI | Development |
| Navtemadlin (KRT-232) | Kartos Therapeutics | Phase 1/Phase 2 |
| QL325 | QLSF Biotherapeutics | Phase 1 |
| NPM1 Testing in AML | Diatech Pharmacogenetics | Commercial |
| Joint Development for AML | Ordaos Bio | Pre-clinical |
| AL8326 | Shanghai Allist Pharmaceuticals | Phase II |